Abstract:Fully capturing cellular state requires examining genomic, epigenomic, transcriptomic, proteomic, and other assays for a biological sample and comprehensive computational modeling to reason with the complex and sometimes conflicting measurements. Modeling these so-called multi-omic data is especially beneficial in disease analysis, where observations across omic data types may reveal unexpected patient groupings and inform clinical outcomes and treatments. We present Multi-omic Pathway Analysis of Cancer (MPAC), a computational framework that interprets multi-omic data through prior knowledge from biological pathways. MPAC uses network relationships encoded in pathways using a factor graph to infer consensus activity levels for proteins and associated pathway entities from multi-omic data, runs permutation testing to eliminate spurious activity predictions, and groups biological samples by pathway activities to prioritize proteins with potential clinical relevance. Using DNA copy number alteration and RNA-seq data from head and neck squamous cell carcinoma patients from The Cancer Genome Atlas as an example, we demonstrate that MPAC predicts a patient subgroup related to immune responses not identified by analysis with either input omic data type alone. Key proteins identified via this subgroup have pathway activities related to clinical outcome as well as immune cell compositions. Our MPAC R package, available at https://bioconductor.org/packages/MPAC, enables similar multi-omic analyses on new datasets.

What problem does this paper attempt to address?

The problem addressed in this paper is how to infer cancer pathway activity from multiple omics datasets. The research team developed a computational framework called Multi-omic Pathway Analysis of Cancer (MPAC), which utilizes prior knowledge of biological pathways to interpret multiple omics data. MPAC infers consistent activity levels of proteins and their associated pathway entities from the multiple omics data using network relationships represented by factor graphs. It performs random testing to eliminate false predictions and groups biological samples based on pathway activity to prioritize the identification of proteins with potential clinical significance. In the data from patients with head and neck squamous cell carcinoma, MPAC predicted a patient subgroup associated with immune response, which cannot be discovered when analyzing individual omics data types alone. The paper emphasizes the advantages of MPAC in understanding cancer mechanisms, particularly its ability to provide comprehensive insights into molecular basis and clinical impact, and has implemented an automated workflow for multi-omics analysis using the R package.

MPAC: a computational framework for inferring cancer pathway activities from multi-omic data